A股異動 | 紅太陽大漲近7% 與江蘇中邦製藥簽署75%乙醇消毒液協議
格隆匯2月10日丨紅太陽(000525.SZ)大漲近7%,報8.61元,總市值50億元。

紅太陽2月9日晚間公告稱,2月9日,紅太陽與江蘇中邦製藥簽署“紅太陽牌75%乙醇消毒液”產品全國獨家總代理框架協議。江蘇中邦製藥保證未來三個月產品月產量不少於7000噸。江蘇中邦製藥是紅太陽產業集團旗下高新技術實業公司。江蘇中邦製藥主動投身於疫情防控戰,快速建成年產10萬噸75%乙醇消毒液生產線首期項目,而且還順利取得了“紅太陽牌75%乙醇消毒液”產品生產企業衞生許可證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.